Silicon Investor (SI) -- The First Internet Community

STOCKTALK

POLITICS
PASTIMES

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (11426)	8/20/1999 1:52:00 PM
From: aknahow	Respond to of 17367

Not an exact answer to your question but for Trauma alone the extended P II tried out higher and longer periods of dosage. but when the P III was designed the selected dosage and days of treatment were the same as inital P II. Asked XOMA by e-mail and thats what they said. I do not think the same dosage was used for Meningococcemia but have not checked, too lazy.